CNC Centene Corporation
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.…
Industry Peers
Healthcare PlansKey Statistics
About Centene (NYSE: CNC)
›
Centene (NYSE: CNC) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Healthcare Plans industry, part of the Healthcare sector, and reports about 61,100 employees.
The shares were at 65.58 USD on 19 November 2026, up 76.9% over 52 weeks. Its 52-week range is 31.63 USD to 78.07 USD: the price is 16.0% below the high and 107.3% above the low.
At a market capitalisation of 32.47B USD, it trades at 22.5 times trailing earnings and 11.8 times forward earnings. The median trailing P/E of its 9 largest Healthcare Plans peers is 18.9, a premium of 19% for CNC.
Centene reports return on equity of -33.4%, an operating margin of 1.9% and flat revenue year over year.
It holds more cash than debt, a net cash position of 8.04B USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 18 analysts cover the stock, with an average rating of Buy; their mean price target of 76.00 USD is 15.9% above the current price. The next earnings report is expected on 5 February 2027.